马夫利木单抗治疗巨细胞动脉炎的有效性与安全性:一项2期随机双盲安慰剂对照试验
这项2期双盲安慰剂对照试验纳入经活检或影像确诊的巨细胞动脉炎患者,随机接受马夫利木单抗150 mg或安慰剂皮下注射每2周一次,两组均接受26周泼尼松减量。马夫利木单抗组至第26周复发时间优于安慰剂组(HR 0.38;95%CI 0.15-0.92;p=0.026),第26周持续缓解率83% vs 50%(p=0.0038)。
要点
- 马夫利木单抗组第26周复发率19%(8例),安慰剂组46%(13例)。
- 至复发时间安慰剂组中位25.1周,马夫利木单抗组中位未达到(HR 0.38;95%CI 0.15-0.92;p=0.026)。
- 第26周持续缓解率马夫利木单抗组83% vs 安慰剂组50%(p=0.0038)。
核心结论
- 在巨细胞动脉炎患者中,马夫利木单抗联合26周泼尼松方案在至第26周复发时间和持续缓解方面优于安慰剂联合26周泼尼松方案。
- 需要更长时间的治疗来确定应答的持久性并量化马夫利木单抗减少糖皮质激素用量的潜力。
研究设计与样本
- 2期、双盲、安慰剂对照试验,在50个中心(北美、欧洲、澳大利亚)纳入经活检确诊或影像确诊的巨细胞动脉炎患者。
- 纳入标准要求基线前6周内有活动性疾病;处于糖皮质激素诱导缓解的患者按3:2比例随机分配至马夫利木单抗150 mg或安慰剂皮下注射每2周一次。
- 两组均接受26周泼尼松减量方案;主要结局为至第26周裁定的复发时间。
- 预设次要疗效结局为通过Kaplan-Meier估计的第26周持续缓解;同时评估安全性。
主要发现
- 42例马夫利木单抗组患者中19%(n=8)发生复发,28例安慰剂组患者中46%(n=13)发生复发。
- 至复发时间(主要结局)安慰剂组中位25.1周,马夫利木单抗组中位未达到(HR 0.38;95%CI 0.15-0.92;p=0.026)。
- 第26周持续缓解率马夫利木单抗组83% vs 安慰剂组50%(p=0.0038)。
- 不良事件发生率马夫利木单抗组78.6%(n=33)vs 安慰剂组89.3%(n=25)。
- 两组均无死亡或视力丧失。
关键数值与推荐
- 主要结局:至第26周复发时间,马夫利木单抗组中位未达到 vs 安慰剂组中位25.1周(HR 0.38;95%CI 0.15-0.92;p=0.026)。
- 次要结局:第26周持续缓解率马夫利木单抗组83% vs 安慰剂组50%(p=0.0038)。
- 安全性:不良事件马夫利木单抗组78.6%(n=33)vs 安慰剂组89.3%(n=25);两组均无死亡或视力丧失。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出需要更长时间的治疗来确定应答的持久性并量化马夫利木单抗减少糖皮质激素用量的潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Granulocyte-macrophage colony-stimulating factor (GM-CSF) is implicated in pathogenesis of giant cell arteritis. We evaluated the efficacy of the GM-CSF receptor antagonist mavrilimumab in maintaining disease remission. METHODS: This phase 2, double-blind, placebo-controlled trial enrolled patients with biopsy-confirmed or imaging-confirmed giant cell arteritis in 50 centres (North America, Europe, Australia). Active disease within 6 weeks of baseline was required for inclusion. Patients in glucocorticoid-induced remission were randomly assigned (3:2 ratio) to mavrilimumab 150 mg or placebo injected subcutaneously every 2 weeks. Both groups received a 26-week prednisone taper. The primary outcome was time to adjudicated flare by week 26. A prespecified secondary efficacy outcome was sustained remission at week 26 by Kaplan-Meier estimation. Safety was also assessed. RESULTS: Of 42 mavrilimumab recipients, flare occurred in 19% (n=8). Of 28 placebo recipients, flare occurred in 46% (n=13). Median time to flare (primary outcome) was 25.1 weeks in the placebo group, but the median was not reached in the mavrilimumab group (HR 0.38; 95% CI 0.15 to 0.92; p=0.026). Sustained remission at week 26 was 83% for mavrilimumab and 50% for placebo recipients (p=0.0038). Adverse events occurred in 78.6% (n=33) of mavrilimumab and 89.3% (n=25) of placebo recipients. No deaths or vision loss occurred in either group. CONCLUSIONS: Mavrilimumab plus 26 weeks of prednisone was superior to placebo plus 26 weeks of prednisone for time to flare by week 26 and sustained remission in patients with giant cell arteritis. Longer treatment is needed to determine response durability and quantify the glucocorticoid-sparing potential of mavrilimumab. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov number: NCT03827018, Europe (EUdraCT number: 2018-001003-36), and Australia (CT-2018-CTN-01 865-1).
引用
- Cid MC, Unizony SH, Blockmans D, et al. Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022. PMID: 35264321. doi:10.1136/annrheumdis-2021-221865
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。